It's A List! Why Is China's Rare Disease List A Major Milestone For Orphan Drug Developers?
Executive Summary
Largely different from the US and EU, China is tackling rare diseases with a first-ever official list of 121 conditions for now, which could be a major milestone for orphan drug developers, some experts say.
You may also be interested in...
Eight For 8: Things You Need To Know About China Biopharma Regulation In 2018
The Pink Sheet's pick of eight major events that captured major regulatory developments in China’s dynamic, highly fluid biopharma scene in 2018.
Rare Diseases: What Makes China A Rising Star?
Top corporate executives are increasingly turning their attention to rare diseases in China as changing regulatory policies provide a rare opening, and aided by more physicians advocating for orphan drug access. What does the first ever report on rare diseases in China have to say about the opportunities and challenges?
Cancer, Orphan, Pediatric Drug Developers Join China Foreign Data Acceptance Party
China officially issues regulation accepting clinical data obtained from overseas studies, with a priority on treatments for critical, rare and pediatric conditions.